Core Content Review

Acromegaly - 2Qs (May 2023)

Alcohol use and cancer risk (March 2021)

Alpha-1 reductase inhibitors and prostate cancer (May 2021)

Anal intraepithelial neoplasia and cancer - 3Qs (July 2018)

Basal cell carcinoma - 2Qs (September 2020)

Borderline ovarian tumors - 3Qs (January 2022)

Brain tumors in children (November 2022)

BRCA testing - 3Qs (November 2023)

BRCA1/2 gene testing (July 2022)

Breast cancer - chemoprophylaxis - 3Qs (September 2022)

Breast cancer - chemoprophylaxis - 3Qs (November 2020)

Breast cancer - chemoprophylaxis - 3Qs (July 2019)

Breast cancer in men - 3Qs (May 2019)

Breast cancer in trans adults - 2Qs (September 2022)

Breast cancer - Genitourinary symptoms - 3Qs (January 2019)

Breast cancer - modifiable risk factors (November 2021)

Breast cancer survivors - Chronic side effects - 4Qs (July 2018)

Breast cancer – triple negative - 4Qs (May 2019)

Breast imaging of dense breasts (January 2023)

Carcinoid syndrome - 2Qs (November 2023)

Cell-free DNA testing (May 2019)

Cervical adenopathy (May 2023)

Cervical adenopathy - 2Qs (March 2020)

Cervical cancer screening - 2Qs (September 2018)

Chronic lymphocytic leukemia (May 2023)

Chronic lymphocytic leukemia - 5Qs (July 2020)

Classic Hodgkin lymphoma - 5Qs (May 2020)

Colon cancer - screening - 2Qs (March 2024)

Colonic polypectomy - follow-up - 2Qs (January 2024)

Common variable immunodeficiency (March 2022)

Cutaneous squamous cell carcinoma (March 2019)

Dermoscopy - 3Qs (March 2024)

Diethelstibestrol exposure (September 2022)

Endometrial cancer - 5Qs (November 2020)

Endometrial polyps - 2Qs (March 2023)

Esophageal cancer (November 2021)

Esophageal cancer - 5Qs (March 2020)

Essential thrombocythemia - 2Qs (January 2024)

Evaluation of bone metastases (January 2023)

Ewing sarcoma (January 2019)

Gallbladder cancer (January 2022)

Gallbladder polyps - 2Qs (May 2024)

Gallbladder polyps - 2Qs (May 2020)

Gastric cancer (July 2022)

Gestational trophoblastic disease (January 2019)

Hepatocellular carcinoma - 4Qs (January 2022)

Hepatocellular carcinoma - 2Qs (September 2018)

High-grade cervical squamous intraepithelial lesion (July 2018)

Hodgkin lymphoma - 2Qs (September 2021)

HPV infection counseling (July 2022)

HPV-related cancers - 3Qs (November 2021)

Inflammatory bowel disease and risk of colon cancer (January 2020)

Kaposis sarcoma (July 2021)

Localized prostate cancer (July 2019)

Lung cancer - 4Qs (January 2019)

Lung cancer in nonsmokers - 3Qs (September 2019)

Lung cancer - screening (September 2022)

Lung cancer screening - 3Qs (November 2021)

Melanoma - 2Qs (July 2019)

Melanoma overview - 2Qs (September 2021)

Melanoma in skin of color - 2Q (September 2021)

Melanoma types - 3Qs (September 2021)

Meningioma (March 2020)

Mesothelioma (July 2021)

Microscopic hematuria (July 2018)

Multiple endocrine neoplasia - 4Qs (January 2022)

Non-Hodgkin lymphoma - 6Qs (May 2022)

Non-lipid statin use - 2Qs (November 2021)

Oral neoplasms - 2Qs (May 2020)

Paget's disease of the breast - 2Qs (September 2021)

Pancreatic cancer -3Qs (March 2021)

Pancreatic cancer screening (January 2020)

Polycythemia vera - 2Qs (January 2024)

Probiotics and cancer prevention (September 2023)

Prostate cancer – chemoprevention (May 2019)

Prostate cancer prevention (May 2024)

Prostate cancer screening - 4Qs (November 2023)

Prostate cancer - treatment options - 4Qs (September 2020)

Rectal cancer - 5Qs (November 2020)

Seizure and headache in a middle-aged man - 4Qs (November 2019)

Syndrome of inappropriate antidiuretic hormone (SIADH) - 3Qs (November 2021)

Tamoxifen - 2Qs (November 2022)

Testicular cancer (May 2022)

Thyroid cancer - 2Qs (July 2022)

Transgender breast cancer risk and screening (September 2020)

Triple negative breast cancer (September 2021)

Unprovoked venous thrombosis - 4Qs (November 2019)

Venous thromboembolism and malignancy - 2Qs (January 2019)